カテゴリー： Market Monitor Global, 世界, 医療/バイオ

複合ワクチンのグローバル市場展望 2023年-2029年：5価ワクチン、4価ワクチン、3価ワクチン、その他

◆英語タイトル：Multiple Vaccine Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23DC16483）

◆商品コード：MMG23DC16483
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年12月
◆ページ数：99
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の複合ワクチン市場規模と予測を収録しています。・世界の複合ワクチン市場：売上、2018年-2023年、2024年-2029年
・世界の複合ワクチン市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の複合ワクチン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「5価ワクチン」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

複合ワクチンのグローバル主要企業は、Sanofi、 GSK、 Mitsubishi Tanabe Pharma、 KM Biologics、 Wuhan Institute of Biological Products、 Walvax Biotechnology、 Chengdu Institute of Biological Products、 Minhai Biotechnologyなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、複合ワクチンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の複合ワクチン市場：タイプ別、2018年-2023年、2024年-2029年
世界の複合ワクチン市場：タイプ別市場シェア、2022年
・5価ワクチン、4価ワクチン、3価ワクチン、その他

世界の複合ワクチン市場：用途別、2018年-2023年、2024年-2029年
世界の複合ワクチン市場：用途別市場シェア、2022年
・大人、幼児、子供

世界の複合ワクチン市場：地域・国別、2018年-2023年、2024年-2029年
世界の複合ワクチン市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における複合ワクチンのグローバル売上、2018年-2023年
・主要企業における複合ワクチンのグローバル売上シェア、2022年
・主要企業における複合ワクチンのグローバル販売量、2018年-2023年
・主要企業における複合ワクチンのグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Sanofi、 GSK、 Mitsubishi Tanabe Pharma、 KM Biologics、 Wuhan Institute of Biological Products、 Walvax Biotechnology、 Chengdu Institute of Biological Products、 Minhai Biotechnology

*************************************************************

・調査・分析レポートの概要
複合ワクチン市場の定義
市場セグメント
世界の複合ワクチン市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の複合ワクチン市場規模
世界の複合ワクチン市場規模：2022年 VS 2029年
世界の複合ワクチン市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの複合ワクチンの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の複合ワクチン製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：5価ワクチン、4価ワクチン、3価ワクチン、その他
複合ワクチンのタイプ別グローバル売上・予測

・用途別市場分析
用途区分：大人、幼児、子供
複合ワクチンの用途別グローバル売上・予測

・地域別市場分析
地域別複合ワクチン市場規模 2022年と2029年
地域別複合ワクチン売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Sanofi、 GSK、 Mitsubishi Tanabe Pharma、 KM Biologics、 Wuhan Institute of Biological Products、 Walvax Biotechnology、 Chengdu Institute of Biological Products、 Minhai Biotechnology
...

This research report provides a comprehensive analysis of the Multiple Vaccine market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Multiple Vaccine market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Multiple Vaccine, challenges faced by the industry, and potential opportunities for market players.
The global Multiple Vaccine market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Multiple Vaccine market presents opportunities for various stakeholders, including Adult, Infants and Children. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Multiple Vaccine market. Additionally, the growing consumer demand present avenues for market expansion.
The global Multiple Vaccine market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
The process of upgrading global multi-vaccine products is a process of solidifying the competitive landscape.
Key Features:
The research report on the Multiple Vaccine market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Multiple Vaccine market.
Market Overview: The report provides a comprehensive overview of the Multiple Vaccine market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Pentavalent Vaccine, Quadruple Vaccine), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Multiple Vaccine market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Multiple Vaccine market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Multiple Vaccine market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Multiple Vaccine market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Multiple Vaccine market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Multiple Vaccine market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Multiple Vaccine, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Multiple Vaccine market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Multiple Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Pentavalent Vaccine
Quadruple Vaccine
Triple Vaccine
Others
Market segment by Application
Adult
Infants and Children
Global Multiple Vaccine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Sanofi
GSK
Mitsubishi Tanabe Pharma
KM Biologics
Wuhan Institute of Biological Products
Walvax Biotechnology
Chengdu Institute of Biological Products
Minhai Biotechnology
Outline of Major Chapters:
Chapter 1: Introduces the definition of Multiple Vaccine, market overview.
Chapter 2: Global Multiple Vaccine market size in revenue and volume.
Chapter 3: Detailed analysis of Multiple Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Multiple Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Multiple Vaccine capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Multiple Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Multiple Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Multiple Vaccine Overall Market Size
2.1 Global Multiple Vaccine Market Size: 2022 VS 2029
2.2 Global Multiple Vaccine Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Multiple Vaccine Sales: 2018-2029
3 Company Landscape
3.1 Top Multiple Vaccine Players in Global Market
3.2 Top Global Multiple Vaccine Companies Ranked by Revenue
3.3 Global Multiple Vaccine Revenue by Companies
3.4 Global Multiple Vaccine Sales by Companies
3.5 Global Multiple Vaccine Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Multiple Vaccine Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Multiple Vaccine Product Type
3.8 Tier 1, Tier 2 and Tier 3 Multiple Vaccine Players in Global Market
3.8.1 List of Global Tier 1 Multiple Vaccine Companies
3.8.2 List of Global Tier 2 and Tier 3 Multiple Vaccine Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Multiple Vaccine Market Size Markets, 2022 & 2029
4.1.2 Pentavalent Vaccine
4.1.3 Quadruple Vaccine
4.1.4 Triple Vaccine
4.1.5 Others
4.2 By Type – Global Multiple Vaccine Revenue & Forecasts
4.2.1 By Type – Global Multiple Vaccine Revenue, 2018-2023
4.2.2 By Type – Global Multiple Vaccine Revenue, 2024-2029
4.2.3 By Type – Global Multiple Vaccine Revenue Market Share, 2018-2029
4.3 By Type – Global Multiple Vaccine Sales & Forecasts
4.3.1 By Type – Global Multiple Vaccine Sales, 2018-2023
4.3.2 By Type – Global Multiple Vaccine Sales, 2024-2029
4.3.3 By Type – Global Multiple Vaccine Sales Market Share, 2018-2029
4.4 By Type – Global Multiple Vaccine Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Multiple Vaccine Market Size, 2022 & 2029
5.1.2 Adult
5.1.3 Infants and Children
5.2 By Application – Global Multiple Vaccine Revenue & Forecasts
5.2.1 By Application – Global Multiple Vaccine Revenue, 2018-2023
5.2.2 By Application – Global Multiple Vaccine Revenue, 2024-2029
5.2.3 By Application – Global Multiple Vaccine Revenue Market Share, 2018-2029
5.3 By Application – Global Multiple Vaccine Sales & Forecasts
5.3.1 By Application – Global Multiple Vaccine Sales, 2018-2023
5.3.2 By Application – Global Multiple Vaccine Sales, 2024-2029
5.3.3 By Application – Global Multiple Vaccine Sales Market Share, 2018-2029
5.4 By Application – Global Multiple Vaccine Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Multiple Vaccine Market Size, 2022 & 2029
6.2 By Region – Global Multiple Vaccine Revenue & Forecasts
6.2.1 By Region – Global Multiple Vaccine Revenue, 2018-2023
6.2.2 By Region – Global Multiple Vaccine Revenue, 2024-2029
6.2.3 By Region – Global Multiple Vaccine Revenue Market Share, 2018-2029
6.3 By Region – Global Multiple Vaccine Sales & Forecasts
6.3.1 By Region – Global Multiple Vaccine Sales, 2018-2023
6.3.2 By Region – Global Multiple Vaccine Sales, 2024-2029
6.3.3 By Region – Global Multiple Vaccine Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Multiple Vaccine Revenue, 2018-2029
6.4.2 By Country – North America Multiple Vaccine Sales, 2018-2029
6.4.3 US Multiple Vaccine Market Size, 2018-2029
6.4.4 Canada Multiple Vaccine Market Size, 2018-2029
6.4.5 Mexico Multiple Vaccine Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Multiple Vaccine Revenue, 2018-2029
6.5.2 By Country – Europe Multiple Vaccine Sales, 2018-2029
6.5.3 Germany Multiple Vaccine Market Size, 2018-2029
6.5.4 France Multiple Vaccine Market Size, 2018-2029
6.5.5 U.K. Multiple Vaccine Market Size, 2018-2029
6.5.6 Italy Multiple Vaccine Market Size, 2018-2029
6.5.7 Russia Multiple Vaccine Market Size, 2018-2029
6.5.8 Nordic Countries Multiple Vaccine Market Size, 2018-2029
6.5.9 Benelux Multiple Vaccine Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Multiple Vaccine Revenue, 2018-2029
6.6.2 By Region – Asia Multiple Vaccine Sales, 2018-2029
6.6.3 China Multiple Vaccine Market Size, 2018-2029
6.6.4 Japan Multiple Vaccine Market Size, 2018-2029
6.6.5 South Korea Multiple Vaccine Market Size, 2018-2029
6.6.6 Southeast Asia Multiple Vaccine Market Size, 2018-2029
6.6.7 India Multiple Vaccine Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Multiple Vaccine Revenue, 2018-2029
6.7.2 By Country – South America Multiple Vaccine Sales, 2018-2029
6.7.3 Brazil Multiple Vaccine Market Size, 2018-2029
6.7.4 Argentina Multiple Vaccine Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Multiple Vaccine Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Multiple Vaccine Sales, 2018-2029
6.8.3 Turkey Multiple Vaccine Market Size, 2018-2029
6.8.4 Israel Multiple Vaccine Market Size, 2018-2029
6.8.5 Saudi Arabia Multiple Vaccine Market Size, 2018-2029
6.8.6 UAE Multiple Vaccine Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Sanofi
7.1.1 Sanofi Company Summary
7.1.2 Sanofi Business Overview
7.1.3 Sanofi Multiple Vaccine Major Product Offerings
7.1.4 Sanofi Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.1.5 Sanofi Key News & Latest Developments
7.2 GSK
7.2.1 GSK Company Summary
7.2.2 GSK Business Overview
7.2.3 GSK Multiple Vaccine Major Product Offerings
7.2.4 GSK Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.2.5 GSK Key News & Latest Developments
7.3 Mitsubishi Tanabe Pharma
7.3.1 Mitsubishi Tanabe Pharma Company Summary
7.3.2 Mitsubishi Tanabe Pharma Business Overview
7.3.3 Mitsubishi Tanabe Pharma Multiple Vaccine Major Product Offerings
7.3.4 Mitsubishi Tanabe Pharma Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.3.5 Mitsubishi Tanabe Pharma Key News & Latest Developments
7.4 KM Biologics
7.4.1 KM Biologics Company Summary
7.4.2 KM Biologics Business Overview
7.4.3 KM Biologics Multiple Vaccine Major Product Offerings
7.4.4 KM Biologics Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.4.5 KM Biologics Key News & Latest Developments
7.5 Wuhan Institute of Biological Products
7.5.1 Wuhan Institute of Biological Products Company Summary
7.5.2 Wuhan Institute of Biological Products Business Overview
7.5.3 Wuhan Institute of Biological Products Multiple Vaccine Major Product Offerings
7.5.4 Wuhan Institute of Biological Products Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.5.5 Wuhan Institute of Biological Products Key News & Latest Developments
7.6 Walvax Biotechnology
7.6.1 Walvax Biotechnology Company Summary
7.6.2 Walvax Biotechnology Business Overview
7.6.3 Walvax Biotechnology Multiple Vaccine Major Product Offerings
7.6.4 Walvax Biotechnology Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.6.5 Walvax Biotechnology Key News & Latest Developments
7.7 Chengdu Institute of Biological Products
7.7.1 Chengdu Institute of Biological Products Company Summary
7.7.2 Chengdu Institute of Biological Products Business Overview
7.7.3 Chengdu Institute of Biological Products Multiple Vaccine Major Product Offerings
7.7.4 Chengdu Institute of Biological Products Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.7.5 Chengdu Institute of Biological Products Key News & Latest Developments
7.8 Minhai Biotechnology
7.8.1 Minhai Biotechnology Company Summary
7.8.2 Minhai Biotechnology Business Overview
7.8.3 Minhai Biotechnology Multiple Vaccine Major Product Offerings
7.8.4 Minhai Biotechnology Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.8.5 Minhai Biotechnology Key News & Latest Developments
8 Global Multiple Vaccine Production Capacity, Analysis
8.1 Global Multiple Vaccine Production Capacity, 2018-2029
8.2 Multiple Vaccine Production Capacity of Key Manufacturers in Global Market
8.3 Global Multiple Vaccine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Multiple Vaccine Supply Chain Analysis
10.1 Multiple Vaccine Industry Value Chain
10.2 Multiple Vaccine Upstream Market
10.3 Multiple Vaccine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Multiple Vaccine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Multiple Vaccine in Global Market
Table 2. Top Multiple Vaccine Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Multiple Vaccine Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Multiple Vaccine Revenue Share by Companies, 2018-2023
Table 5. Global Multiple Vaccine Sales by Companies, (M Doses), 2018-2023
Table 6. Global Multiple Vaccine Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Multiple Vaccine Price (2018-2023) & (US$/Dose)
Table 8. Global Manufacturers Multiple Vaccine Product Type
Table 9. List of Global Tier 1 Multiple Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Multiple Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Multiple Vaccine Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Multiple Vaccine Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Multiple Vaccine Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Multiple Vaccine Sales (M Doses), 2018-2023
Table 15. By Type - Global Multiple Vaccine Sales (M Doses), 2024-2029
Table 16. By Application – Global Multiple Vaccine Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Multiple Vaccine Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Multiple Vaccine Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Multiple Vaccine Sales (M Doses), 2018-2023
Table 20. By Application - Global Multiple Vaccine Sales (M Doses), 2024-2029
Table 21. By Region – Global Multiple Vaccine Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Multiple Vaccine Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Multiple Vaccine Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Multiple Vaccine Sales (M Doses), 2018-2023
Table 25. By Region - Global Multiple Vaccine Sales (M Doses), 2024-2029
Table 26. By Country - North America Multiple Vaccine Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Multiple Vaccine Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Multiple Vaccine Sales, (M Doses), 2018-2023
Table 29. By Country - North America Multiple Vaccine Sales, (M Doses), 2024-2029
Table 30. By Country - Europe Multiple Vaccine Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Multiple Vaccine Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Multiple Vaccine Sales, (M Doses), 2018-2023
Table 33. By Country - Europe Multiple Vaccine Sales, (M Doses), 2024-2029
Table 34. By Region - Asia Multiple Vaccine Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Multiple Vaccine Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Multiple Vaccine Sales, (M Doses), 2018-2023
Table 37. By Region - Asia Multiple Vaccine Sales, (M Doses), 2024-2029
Table 38. By Country - South America Multiple Vaccine Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Multiple Vaccine Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Multiple Vaccine Sales, (M Doses), 2018-2023
Table 41. By Country - South America Multiple Vaccine Sales, (M Doses), 2024-2029
Table 42. By Country - Middle East & Africa Multiple Vaccine Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Multiple Vaccine Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Multiple Vaccine Sales, (M Doses), 2018-2023
Table 45. By Country - Middle East & Africa Multiple Vaccine Sales, (M Doses), 2024-2029
Table 46. Sanofi Company Summary
Table 47. Sanofi Multiple Vaccine Product Offerings
Table 48. Sanofi Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 49. Sanofi Key News & Latest Developments
Table 50. GSK Company Summary
Table 51. GSK Multiple Vaccine Product Offerings
Table 52. GSK Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 53. GSK Key News & Latest Developments
Table 54. Mitsubishi Tanabe Pharma Company Summary
Table 55. Mitsubishi Tanabe Pharma Multiple Vaccine Product Offerings
Table 56. Mitsubishi Tanabe Pharma Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 57. Mitsubishi Tanabe Pharma Key News & Latest Developments
Table 58. KM Biologics Company Summary
Table 59. KM Biologics Multiple Vaccine Product Offerings
Table 60. KM Biologics Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 61. KM Biologics Key News & Latest Developments
Table 62. Wuhan Institute of Biological Products Company Summary
Table 63. Wuhan Institute of Biological Products Multiple Vaccine Product Offerings
Table 64. Wuhan Institute of Biological Products Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 65. Wuhan Institute of Biological Products Key News & Latest Developments
Table 66. Walvax Biotechnology Company Summary
Table 67. Walvax Biotechnology Multiple Vaccine Product Offerings
Table 68. Walvax Biotechnology Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 69. Walvax Biotechnology Key News & Latest Developments
Table 70. Chengdu Institute of Biological Products Company Summary
Table 71. Chengdu Institute of Biological Products Multiple Vaccine Product Offerings
Table 72. Chengdu Institute of Biological Products Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 73. Chengdu Institute of Biological Products Key News & Latest Developments
Table 74. Minhai Biotechnology Company Summary
Table 75. Minhai Biotechnology Multiple Vaccine Product Offerings
Table 76. Minhai Biotechnology Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 77. Minhai Biotechnology Key News & Latest Developments
Table 78. Multiple Vaccine Production Capacity (M Doses) of Key Manufacturers in Global Market, 2021-2023 (M Doses)
Table 79. Global Multiple Vaccine Capacity Market Share of Key Manufacturers, 2021-2023
Table 80. Global Multiple Vaccine Production by Region, 2018-2023 (M Doses)
Table 81. Global Multiple Vaccine Production by Region, 2024-2029 (M Doses)
Table 82. Multiple Vaccine Market Opportunities & Trends in Global Market
Table 83. Multiple Vaccine Market Drivers in Global Market
Table 84. Multiple Vaccine Market Restraints in Global Market
Table 85. Multiple Vaccine Raw Materials
Table 86. Multiple Vaccine Raw Materials Suppliers in Global Market
Table 87. Typical Multiple Vaccine Downstream
Table 88. Multiple Vaccine Downstream Clients in Global Market
Table 89. Multiple Vaccine Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Multiple Vaccine Segment by Type in 2022
Figure 2. Multiple Vaccine Segment by Application in 2022
Figure 3. Global Multiple Vaccine Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Multiple Vaccine Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Multiple Vaccine Revenue, 2018-2029 (US$, Mn)
Figure 7. Multiple Vaccine Sales in Global Market: 2018-2029 (M Doses)
Figure 8. The Top 3 and 5 Players Market Share by Multiple Vaccine Revenue in 2022
Figure 9. By Type - Global Multiple Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Multiple Vaccine Revenue Market Share, 2018-2029
Figure 11. By Type - Global Multiple Vaccine Sales Market Share, 2018-2029
Figure 12. By Type - Global Multiple Vaccine Price (US$/Dose), 2018-2029
Figure 13. By Application - Global Multiple Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Multiple Vaccine Revenue Market Share, 2018-2029
Figure 15. By Application - Global Multiple Vaccine Sales Market Share, 2018-2029
Figure 16. By Application - Global Multiple Vaccine Price (US$/Dose), 2018-2029
Figure 17. By Region - Global Multiple Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Multiple Vaccine Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Multiple Vaccine Revenue Market Share, 2018-2029
Figure 20. By Region - Global Multiple Vaccine Sales Market Share, 2018-2029
Figure 21. By Country - North America Multiple Vaccine Revenue Market Share, 2018-2029
Figure 22. By Country - North America Multiple Vaccine Sales Market Share, 2018-2029
Figure 23. US Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Multiple Vaccine Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Multiple Vaccine Sales Market Share, 2018-2029
Figure 28. Germany Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 29. France Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Multiple Vaccine Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Multiple Vaccine Sales Market Share, 2018-2029
Figure 37. China Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 41. India Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Multiple Vaccine Revenue Market Share, 2018-2029
Figure 43. By Country - South America Multiple Vaccine Sales Market Share, 2018-2029
Figure 44. Brazil Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Multiple Vaccine Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Multiple Vaccine Sales Market Share, 2018-2029
Figure 48. Turkey Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 52. Global Multiple Vaccine Production Capacity (M Doses), 2018-2029
Figure 53. The Percentage of Production Multiple Vaccine by Region, 2022 VS 2029
Figure 54. Multiple Vaccine Industry Value Chain
Figure 55. Marketing Channels

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 複合ワクチンのグローバル市場展望 2023年-2029年：5価ワクチン、4価ワクチン、3価ワクチン、その他(Multiple Vaccine Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

複合ワクチンのグローバル市場展望 2023年-2029年：5価ワクチン、4価ワクチン、3価ワクチン、その他

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp